Tuesday, October 4, 2022


Biotechnology News Magazine

Dr. Bruno Paquin Appointed Permanent Chief Executive Officer of CPDC

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 10, 2021

Dr. Bruno Paquin’s appointment became effective on March 4, 2021.

Dr. John Thornback, Chair of the Board of Directors said,We are pleased to announce that Bruno Paquin has been appointed CEO of CPDC with immediate effect. The Board feels that Bruno has done an excellent job as interim CEO over the past few months and we are looking forward to working with Bruno, and everyone in the CPDC family, our clients, and employees, as he leads us through the next phases of development to a successful future.

Dr. Paquin joined CPDC in 2018, where he supported the Centre as Senior Director of Business Development.  Prior to joining CPDC, Bruno was VP of Business Development at Immuni T from 2011 to 2018, where his role was central to the growth of the company and to building a pipeline of sponsored research programs. Prior to Immuni T, Bruno started as the Head of the Technology Development Unit at Genizon Biosciences to become the Executive Director, Head of Business Development, from 2000 to 2011. Bruno received his PhD in Biochemistry from Université de Montréal.

Bruno Paquin said, “I am honored to be named CPDC’s CEO and thankful to the Chair and all the members of the Board of Directors for their confidence.  The CPDC is an exceptional organization transforming patients’ life by fostering the development of revolutionizing drugs.  With the support of the leadership team and that of all the employees, I look forward to leading CPDC to its continuing success and shaping its bright future.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine